This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sticherling, C. Articles by Morady, F. Search for Related Content PubMed PubMed Citation Articles by Sticherling, C. Articles by Morady, F. Social Bookmarking                         What's this?

Effects of Diltiazem and Esmolol on Cycle Length and Spontaneous Conversion of Atrial Fibrillation

Division of Cardiology, Department of Internal Medicine, University Hospital Benjamin Franklin, Free University of Berlin, Germany

Hiroshi Tada, MD

William Hsu, PhD

Anton C. Bares, BS

Hakan Oral, MD

Frank Pelosi, MD

Bradley P. Knight, MD

S. Adam Strickberger, MD

Fred Morady, MD

Division of Cardiology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI

Background: Calcium channel blocking agents have been shown to prolong the duration of atrial fibrillation. This study compared the effects of intravenous diltiazem and esmolol on the cycle length and conversion rate of pacing-induced atrial fibrillation.

Methods and Results: In 41 adults without structural heart disease, atrial fibrillation was induced by rapid atrial pacing. After 3 minutes, either diltiazem (n = 13), esmolol (n = 15), or saline (n = 13) was infused. In the diltiazem group, the atrial fibrillation cycle length shortened by a mean of 43 milliseconds and became significantly shorter than in the control group, while the atrial fibrillation cycle length in the esmolol group did not change. Spontaneous termination of atrial fibrillation occurred significantly less often in the diltiazem group (23%) than in the esmolol (67%, P < 0.05) or placebo groups (77%, P = 0.01).

Conclusions: Intravenous diltiazem shortens the atrial fibrillation cycle length and lowers the probability of spontaneous conversion of recent-onset atrial fibrillation to sinus rhythm. These results suggest that the use of diltiazem for acute rate control may unwittingly prolong the duration of recent-onset atrial fibrillation.

Key Words: esmolol • diltiazem • atrial fibrillation • cardioversion

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 7, No. 2, 81-88 (2002)
DOI: 10.1177/107424840200700204


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Hassan, S. Ahmad, D. Kamalakannan, R. Khoury, E. Kakish, V. Maria, S. Ahmed, L. A. Pires, S. L. Kronick, H. Oral, et al. Conversion of Atrial Fibrillation to Sinus Rhythm During Treatment With Intravenous Esmolol or Diltiazem: A Prospective, Randomized Comparison Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 227 - 231. [Abstract] [PDF]

				Part 7.3: Management of Symptomatic Bradycardia and Tachycardia Circulation, December 13, 2005; 112(24_suppl): IV-67 - IV-77. [Full Text] [PDF]

				Part 4: Advanced Life Support Circulation, November 29, 2005; 112(22_suppl): III-25 - III-54. [Full Text] [PDF]